Back to top
more

Compass Therapeutics, Inc. (CMPX)

(Delayed Data from NSDQ)

$0.90 USD

0.90
373,735

-0.06 (-6.52%)

Updated Aug 7, 2024 03:59 PM ET

After-Market: $0.90 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Brokerage Reports

Research for CMPX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Compass Therapeutics, Inc. [CMPX]

Reports for Purchase

Showing records 1 - 20 ( 76 total )

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

06/03/2024

Company Report

Pages: 10

Phase 1 Study Results at ASCO Showcase Potential of CTX-471 as Monotherapy Treatment in Advanced Solid Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

05/24/2024

Industry Report

Pages: 25

Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

05/16/2024

Company Report

Pages: 6

Doc Survey Highlights Deep Need in Advanced CRC; We Believe CTX-009 Can Raise the Bar

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/14/2024

Company Report

Pages: 8

1Q24 Results; Pipeline Continues to Advance; Top-Line CRC Phase 2 Results On Track for Mid-24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/13/2024

Company Report

Pages: 6

Q1 Financials; COMPANION-003 CRC Data Update on Track for mid:24

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

04/25/2024

Industry Report

Pages: 9

Biotechnology- ASCO 2024 Abstract Titles for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

04/16/2024

Daily Note

Pages: 6

Phase 1 CTX-8371 Trial Begins With Important Clinical Pipeline Expansion; Key ''009 Results Upcoming

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

04/10/2024

Company Report

Pages: 8

CTX-009 and CTX-471 Combo Therapy at AACR Suggests New Opportunities for Pipeline Growth

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

03/22/2024

Daily Note

Pages: 12

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/21/2024

Company Report

Pages: 6

2023 Results; All Eyes on Key Data Updates For CTX-009; Top-line CRC Phase 2 Results Expected By Mid-24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/21/2024

Company Report

Pages: 5

Q4/FY23 Financials; An Exciting Time for CTX-009

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

01/05/2024

Daily Note

Pages: 4

Guiding for 2024: CTX-009 Clinical Data Ahead; CTX-471 Positive Updates

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

01/05/2024

Company Report

Pages: 6

Multiple Important Pipeline Updates to Come; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/09/2023

Company Report

Pages: 6

3Q23 Results; Oncology Portfolio Stays the Course With Multiple Clinical Updates in 4Q23 and 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

11/09/2023

Company Report

Pages: 6

Q3 Financials; CTX-009 CRC Data Ahead in 4Q:23

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/04/2023

Daily Note

Pages: 24

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/03/2023

Company Report

Pages: 6

Q2 Financials; CTX-009 CRC Data in 2H:23, BTC Combo Data Delayed to 2H:24

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Company: Compass Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

05/05/2023

Daily Note

Pages: 21

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

// eof